July 2022 • US $3,850
The administration of therapeutic immune modulators is becoming an increasingly important healthcare treatment option for a growing number of diseases and indications having broad implications for patient health and well-being. But to fully exploit the value of this class of therapeutics in both human and commercial terms, developers must successfully navigate the inherent limitations of drug storage and administration, moving away from infusion and toward injection as a route of administration. Antibody drug products indicated for chronic conditions such as autoimmunity are often re-formulated, re-packaged and re-labeled into injectable form and re-introduced two to three years post-market launch to address the growing economic pressure and patient desire to avoid the need for out-patient infusion in favor of self-injection. This report describes key factors in the trend toward patient enablement and self-administration.
Self-administered Autoimmune Injectables – What You Will Learn
– What approved drugs indicated for autoimmune conditions are marketed for self-administration, what is the as-supplied packaging, and who markets them?
– What are the major factors driving the migration of infusible drugs for treating autoimmunity to formulations that can be packaged and administered subcutaneously?
– What is the size of the market for self-administered autoimmune injectable drugs today, who are the market share leaders, and what will the market share be in 2028?
– How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
– What are the essential design factors, technologies and market development issues for devices that can deliver injectable autoimmune drugs subcutaneously?
– What are the significant economic, technology, and regulatory factors affecting the market for immunotherapeutic drugs?
Summary of Contents
Drug Supply Chain Activity
Product Design and Enablement Factors
Ease of Use
Pre- and Post-Marketing Device Evolution
Self-administered Enabling Devices
Device Selection – Stability and Material Issues
Physioject (Becton Dickinson)
Enbrel SureClick (Amgen)
SmartJect (PA Consulting/Centocor)
Pegasys Proclick (Genentech/Roche)
Special Feature Autoinjectors
Dual Chamber Pens
Self-administered Therapeutic Autoimmune Drugs
Benlysta (GSK/Human Genome Sciences)
Tumor Necrosis Factors
Adult Rheumatoid Arthritis
Juvenile Idiopathic Arthritis